Amgen needs to get lucky with Repatha
- Amgen to boost its well diversified portfolio with upcoming FDA decisions.
- The company is looking to push Repatha to become its star performer.
- The company stock, at 52 weeks high, looks overheated at the moment.
In an earlier article on Amgen (AMGN), titled Amgen: A Dividend Powerhouse Despite A Maturing Portfolio, I discussed how AMGN’s excellent dividend run makes it interesting despite a 19% run up this year so far (at that point in July). The stock has now moved up to 30%, and it may be time to rethink AMGN.
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.